Corvus Pharmaceuticals CRVS
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$171.5K (9 inflow days, 11 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 29.3% of shares outstanding.
Largest holders
By investor type
Reported short interest has fallen from 22.74% to 21.11% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Fisher Investments | Mutual Fund | 2026/Q3 | +1,040,606 | 1.2% |
| Connor, Clark & Lunn Investment Management Ltd. | Mutual Fund | 2026/Q3 | +205,512 | 0.5% |
| SEI Investments Company | Mutual Fund | 2026/Q3 | +101,509 | 0.2% |
| Squarepoint OPS LLC | Hedge Fund | 2026/Q3 | +85,818 | 0.2% |
| Nuveen Asset Management LLC | Insurance Company | 2026/Q3 | +152,628 | 0.2% |
| BlackRock | Mutual Fund | 2026/Q3 | +978,389 | 8.5% |
| State Street Global Advisors | Mutual Fund | 2026/Q3 | +908,099 | 5.3% |
| T. Rowe Price Group, Inc. | Mutual Fund | 2026/Q3 | +871,826 | 4.5% |
| Eversept Partners, L.P. | Hedge Fund | 2026/Q3 | +747,994 | 0.9% |
| Bank of America Corporation | Public Company | 2026/Q3 | +520,794 | 0.9% |
| Wellington Management Group | Mutual Fund | 2026/Q3 | +413,115 | 3.2% |
| Perceptive Advisors LLC | VC/PE Fund | 2026/Q3 | +375,000 | 3.2% |
| Braidwell LP | Hedge Fund | 2026/Q3 | +373,500 | 2.5% |
| Trexquant Investment LP | Hedge Fund | 2026/Q3 | +296,347 | 0.4% |
| Two Sigma Investments, LP | Hedge Fund | 2026/Q3 | +245,339 | 0.9% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 12 Nov 2026 | Jeffrey Arcara | Senior VP & Chief Business Officer | Open Market Acquisition | +4,500 | $11.46 | 4,500 |
| 10 Jun 2026 | Richard van den Broek | Independent Director | Other Derivative Acquisition | +15,000 | $11.60 | 15,000 |
| 10 Jun 2026 | Linda Grais | Independent Director | Other Derivative Acquisition | +15,000 | $11.60 | 15,000 |
| 10 Jun 2026 | Ian T. Clark | Former Independent Director | Other Derivative Acquisition | +15,000 | $11.60 | 15,000 |
| 10 Jun 2026 | Peter Thompson | Co-Founder & Independent Director | Other Derivative Acquisition | +15,000 | $11.60 | 15,000 |
| 10 Jun 2026 | David Moore | Independent Director | Open Market Acquisition | +21,700 | $11.53 | 21,700 |
| 10 Jun 2026 | David Moore | Independent Director | Other Derivative Acquisition | +15,000 | $11.60 | 15,000 |
| 17 May 2026 | Richard Miller | Co-Founder, President, CEO & Chairman of the Board | Open Market Acquisition | +6,932 | $12.05 | 2,331,742 |
| 27 Jan 2026 | Peter Thompson | Co-Founder & Independent Director | Derivative Exercise and Retained | +210,000 | $15.00 | 210,000 |
| 3 Dec 2025 | Richard Miller | Co-Founder, President, CEO & Chairman of the Board | Other Derivative Acquisition | +1,000,000 | $8.81 | 1,000,000 |
| 3 Dec 2025 | Leiv Lea | Chief Financial Officer | Other Derivative Acquisition | +400,000 | $8.81 | 400,000 |
| 3 Dec 2025 | Jeffrey Arcara | Senior VP & Chief Business Officer | Other Derivative Acquisition | +100,000 | $8.81 | 100,000 |
| 3 Dec 2025 | William Jones | Senior Vice President of Pharmaceutical Development | Other Derivative Acquisition | +400,000 | $8.81 | 400,000 |
| 1 Oct 2025 | David Moore | Independent Director | Other Derivative Acquisition | +30,000 | $7.04 | 30,000 |
| 26 Jun 2025 | OrbiMed Advisors LLC | Derivative Exercise and Sale | -1,176,332 | $4.16 | 7,165,006 | |
| 26 Jun 2025 | OrbiMed Advisors LLC | Derivative Exercise and Retained | +221,352 | $3.50 | 7,165,006 | |
| 11 Jun 2025 | Linda Grais | Independent Director | Other Derivative Acquisition | +15,000 | $4.24 | 15,000 |
| 11 Jun 2025 | Ian T. Clark | Former Independent Director | Other Derivative Acquisition | +15,000 | $4.24 | 15,000 |
| 11 Jun 2025 | Peter Thompson | Co-Founder & Independent Director | Other Derivative Acquisition | +15,000 | $4.24 | 15,000 |
| 11 Jun 2025 | Scott William Morrison | Former Independent Director | Other Derivative Acquisition | +15,000 | $4.24 | 15,000 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 17,759,451 | 21.1% | 18.9 |
| 15 Oct 2026 | 17,967,756 | 21.4% | 14.9 |
| 30 Sep 2026 | 17,797,751 | 21.2% | 13.3 |
| 15 Sep 2026 | 17,180,341 | 20.4% | 18.2 |
| 31 Aug 2026 | 19,017,840 | 22.6% | 29.6 |
| 14 Aug 2026 | 19,127,098 | 22.7% | 22.5 |
No comments yet — be the first to weigh in on CRVS.
Sign in to join the discussion.